...
首页> 外文期刊>Sleep >Sleep apnea cardiovascular clinical trials - Current status and steps forward: The international collaboration of sleep apnea cardiovascular trialists
【24h】

Sleep apnea cardiovascular clinical trials - Current status and steps forward: The international collaboration of sleep apnea cardiovascular trialists

机译:睡眠呼吸暂停心血管临床试验-现状和进展:睡眠呼吸暂停心血管临床医生的国际合作

获取原文
获取原文并翻译 | 示例
           

摘要

Sleep apnea is a common chronic disease that is associated with coronary heart disease, stroke, heart failure and mortality, although the ability of sleep apnea treatment to reduce cardiovascular morbidity and mortality has not been demonstrated. In contrast to patients seeking treatment in sleep disorders centers, as many as half of individuals with moderate to severe sleep apnea in the general population do not report excessive sleepiness; however, if treatment of sleep apnea were shown to reduce cardiovascular disease risk, this would provide a strong rationale for treatment of sleep apnea even in the absence of daytime sleepiness. This article summarizes the status of clinical trials evaluating the potential cardiovascular benefits of sleep apnea treatment and discusses the challenges of conducting such trials, and introduces the International Collaboration of Sleep Apnea Cardiovascular Trialists (INCOSACT), a clinical research collaboration formed to foster cardiovascular sleep research.
机译:睡眠呼吸暂停是一种常见的慢性疾病,与冠心病,中风,心力衰竭和死亡率有关,尽管尚未证明睡眠呼吸暂停能够降低心血管疾病的发病率和死亡率。与在睡眠障碍中心寻求治疗的患者相反,在普通人群中,多达一半的中度至重度睡眠呼吸暂停患者未报告过度嗜睡。但是,如果显示睡眠呼吸暂停的治疗降低了患心血管疾病的风险,那么即使在没有白天嗜睡的情况下,这也将为治疗睡眠呼吸暂停提供强有力的理由。本文概述了评估睡眠呼吸暂停治疗潜在的心血管益处的临床试验的现状,并讨论了进行此类试验的挑战,并介绍了国际睡眠呼吸暂停心血管试验者合作组织(INCOSACT),这是一项旨在促进心血管睡眠研究的临床研究合作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号